Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII

Cancer Research

Volumn 55, Issue 20, 1995, Pages 4586-4593

  Weiner, Louis M ^a   Clark, Joseph I ^a   Davey, Monica ^a   Li, Wei S ^a   de Palazzo, Irma Garcia ^a   Alpaugh, R Katherine ^a   Ring, David B ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; FC RECEPTOR; GAMMA INTERFERON; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEVER; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTO ONCOGENE; RIGOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; NEUTROPHILS; RECEPTOR, ERBB-2; RECEPTORS, IGG; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0028822836     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lubeck, M. D., Steplewski, Z., Baglia, F., Klein, M. H., Dorrington, K. J., and Koprowski, H. The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J. Immunol., 135: 1299–1304, 1985.
2. Herlyn, D., and Koprowski, H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA, 79: 4761–4765, 1982.
3. Steplewski, Z., Lubeck, M. D., and Koprowski, H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science (Washington DC), 221: 865–867, 1983.
4. Herlyn, D., Herlyn, M., Steplewski, Z., and Koprowski, H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur. J. Immunol., 9: 657–659, 1979.
5. Dillman, R. O. Monoclonal antibodies for treating cancer. Ann. Int. Med., Ill: 592–603, 1989.
6. Garcia de Palazzo, I., Gercel-Taylor, C., Kitson, J., and Weiner, L. M. Potentiation of tumor lysis by a bispecific antibody that binds to CA19–9 antigen and the Fcg receptor expressed by human large granular lymphocytes. Cancer Res., 50: 7123–7128, 1990.
7. Perez, P., Hoffman, R. W., Titus, J. A., and Segal, D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 cross-linked to anti-target cell antibodies. J. Exp. Med., 163: 166–178, 1986.
8. Shen, L., Guyre, P. M., Anderson, C. L., and Fanger, M. W. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-γ and is not blocked by human IgG. J. Immunol., 137: 3378–3382, 1986.
9. Lanzavecchia, A., and Scheidegger, D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol., 17: 105–111, 1987.
10. Ferrini, S., Prigione, I., Miotti, S., Cicone, E., Cantoni, C., Chen, Q., Colnaghi, M. I., and Moretta, L. Bispecific monoclonal antibodies directed to CD 16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int. J. Cancer, 48: 227–233, 1991.
11. Fanger, M. W., Segal, D. M., and Romet-Lemonne, J. L. Bispecific antibodies and targeted cellular cytotoxicity. Immunol. Today, 12: 51–54, 1991.
12. Tutt, A., Stevenson, G. T., and Glennie, N. J. Trispecific F(ab’)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol., 147: 60–69, 1991.
13. George, A. J., Titus, J. A., Jost, C. R., Kurucz, I., Perez, P., Andrew, S. M., Nicholls, P. J., Huston, J. S., and Segal, D. M. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J. Immunol., 152: 1802–1811, 1994.
14. Segal, D. M., and Wunderlich, J. R., Jr. Targeting of cytotoxic cells with hetero-crosslinked antibodies. Cancer Invest., 6: 83–92, 1988.
15. Nitta, T., Sato, K., Yagita, H., Okumura, K., and Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335: 368–371, 1990.
16. Bolhuis, R. L., Lamers, C. H., Goey, S. H., Eggermont, A. M., Trimbos, J. B., Stoter, G., Lanzavecchia, A., di Re, E., Miotti, S., and Raspagliesi, F. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer, 7: 78–81, 1992.
17. Valone, F. H., Kaufman, P. A., Fanger, M. W., Guyre, P. M., and Memoli, V. Phase la/lb trial of bispecific monoclonal antibody (BsMAb) therapy (anti-Her2/neu X anti-CD64) (MDX-210) for breast or ovarian cancers that over express Her-2/neu. Proc. Am. Assoc. Cancer Res., 35: 220, 1994.
18. Ravetch, J. V., and Pemssia, B. Alternative membrane forms of Fc gamma RIII (CD 16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med., 770: 481–497, 1989.
19. Ring, D. B., Shi, T., Hsieh-Ma, S. T., Reeder, J., Eaton, A., and Flatgaard, J. Targeted lysis of human breast cancer cells by human effector cells armed with bispecific antibody 2B1 (anti-c-erbB-2/anti-Fcγ receptor III). In: R. Ceriani (ed.), Proceedings of the Fourth International Workshop on Monoclonal Antibodies and Breast Cancer, San Francisco, California. New York: Plenum Publishing Corp., 1991.
20. Shi, T., Eaton, A. M., and Ring, D. B. Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains. J. Immunol. Methods, 141: 165–175, 1991.
21. Hsieh-ma, S. T., Eaton, A. M., Shi, T., et al. In vitro cytotoxic targeting by human mononuclear cells to bispecific antibody 2B1 recognizing c-erbB-2 protooncogene product and Fey receptor HI. Cancer Res., 52: 6832–6839, 1992.
22. Weiner, L. M., Holmes, M., Richeson, A., Godwin, A., Adams, G. P., Hsieh-Ma, S. T., Ring, D. B., and Alpaugh, R. K. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol., 151: 2877–2886, 1993.
23. Weiner, L. M., Holmes, M., Adams, G. P., LaCreta, F., Watts, P., and Garcia de Palazzo, I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res., 53: 94–100, 1993.
24. Frankel, A. E., Ring, D. B., Tringale, F., and Hsieh-Ma, S. T. Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Response, 4: 273–286, 1985.
25. Fleit, H. B., Wright, S. D., and Unkeless, J. C. Human neutrophil Fey receptor distribution and structure. Proc. Natl. Acad. Sci. USA, 79: 3275–3279, 1982.
26. Garcia de Palazzo, I. E., Klein-Szanto, A., and Weiner, L. M. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies. Int. J. Biomarkers, 8: 233–239, 1993.
27. Rocci, M. L., and Jusko, W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed., 16: 203–216, 1983.
28. van Deventer, S. J., Hart, M., van der Poll, T., Hack, C. E., and Aarden, L. A. Endotoxin and tumor necrosis factor-a-induced interleukin-8 release in humans. J. Infect. Dis., 167: 461–454, 1993.
29. Helle, M., Boeije, L., de Groot, E., de Vos, A., and Aarden, L. Sensitive ELISA for interleukin-6j. Detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol. Methods, 138: 47–56, 1991.
30. van der Poll, T., van Deventer, S. J., Hack, C. E., Wolbink, G. J., Aarden, L. A., Buller, H. R., and ten Cate, J. W. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood, 79: L693-L698, 1992.
31. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs, 10: 239–253, 1992.
32. Ortho Multicenter Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med., 313: 337–342, 1985.
33. Thistlewaite, J. R., Jr., Stuart, J. K., Mayes, J. T., Gaber, A. O., Woodle, S., Buckingham, M. R., and Stuart, F. P. Complication and monitoring of OKT3 therapy. Am. J. Kidney Dis., 11: 112–119, 1988.
34. Norman, D. J., Shield, C. F., Barry, J., Bennett, W. M., Menell, K., Kimball, J., Funnell, B., and Hubert, B. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am. J. Kidney Dis., 11: 107–110, 1988.
35. Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M. R., Oettgen, H. F., and Old, L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a Phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 82: 1242–1246, 1985.
36. Cheung, N. K., Burch, L., Kushner, B. H., and Munn, D. H. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a Phase II trial. Prog. Clin. Biol. Res., 366: 395–400, 1991.
37. Handgretinger, R., Baader, P., Dopfer, R., Klingebiel, T., Reuland, P., Treuner, J., Reisfeld, R. A., and Niethammer, D. A Phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother., 35:199–204, 1992.
38. Qarkson, S. B., Bussel, J. B., Kimberly, R. P., Valinsky, J. E., Nachman, R. L., and Unkeless, J. C. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcy-receptor antibody. N. Engl. J. Med., 314: 1236–1239, 1986.
39. Qarkson, S. B., Kimberly, R. P., Valinsky, J. E., Witmer, M. D., Bussel, J. B., Nachman, R. L., and Unkeless, J. C. Blockade of clearance of immune complexes by an anti-Fey receptor monoclonal antibody. J. Exp. Med., 164: 474–489, 1986.
40. Gaston, R. S., Deierhoi, M. H., Patterson, T., Prasthofer, E., Julian, B. A., Barber, W. H., Laskow, D. A., Diethelm, A. G., and Curtis, J. J. OKT3 first-dose reaction: association with T-cell subsets and cytokine release. Kidney Int., 39: 141–148,1991.
41. Chatenoud, L., Ferran, C., Legendre, C., Thovard, I., Merite, S., Reuter, A., Gevaert, Y., Kreis, H., Franchimort, P., and Bach, J. F. In vivo activation following OKT3 administration. Transplantation (Baltimore), 49: 697–702, 1990.
42. Gleixner, B., Kolb, H. J., Holler, E., Liesenfeld, S., Riedner, C., Miller, E., Seeber, C., Kempeni, J., Moller, A., and Knabe, H. Treatment of a GVHD with OKT3: clinical outcome and side-effects associated with release of TNFa. Bone Marrow Transplant, 8: 93–98, 1991.
43. Ferran, C., Sheehan, K., Dy, M., Schreiber, R., Merite, S., Landais, P., Noel, L. H., Grav, G., Bluestone, J., and Bach, J. F. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vitro T cell activation. Eur. J. Immunol., 20: 509–515, 1990.
44. Kroesen, B. J., Janssen, R., Buter, J., Sleiifer, D., The, I.I., Mulder, N., and de Leij, L. Treatment of renal cell carcinoma using bispecific monoclonal antibodies. Proc. Am. Assoc. Cancer Res., 34: 218, 1993.
45. Tibben, J. G., Boerman, O. C., Claessens, R. A. M. J., Corstens, F. H. M., van Deuren, M., de Mulder, P. H. M., and van der Meer, J. W. M. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab’)2. J. Natl. Cancer Inst., 85: 1003–1004, 1993.
46. Selby, P., Hobbs, S., Viner, C., Jackson, E., Jones, A., Newell, D., Calvert, A. H., McElwain, T., Fearon, K., and Humphreys, J. Tumor necrosis factor in man: clinical and biological observations. Br. J. Cancer, 56: 803–808, 1987.
47. Kimara, K., Taguchi, T., Urushizaki, I., Ohno, R., Abe, O., Furue, H., Hattori, T., Ichihashi, H., Inoguchi, K., and Majima, H. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol., 20: 223–229, 1987.
48. Gallinger, S., Reilly, R. M., Kirsh, J. C., Odze, R. D., Hay, K., Polihronis, J., Damani, M. T., Shpitz, B., and Stern, H. S. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res., 53: 271–278, 1993.
49. Weiner, G. J., and Hillstrom, J. R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol., 147: 4035–4044, 1991.
50. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Trumper, L., Hartmann, F., Diehl, V., van Lier, R., and Pfreundschuh, M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (Washington DC), 264: 833–835, 1994.